Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Celldex Therapeutics (CLDX) EBITDA (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of EBITDA data on record, last reported at -$81.5 million in Q4 2025.

  • For Q4 2025, EBITDA fell 66.01% year-over-year to -$81.5 million; the TTM value through Dec 2025 reached -$258.4 million, down 63.72%, while the annual FY2025 figure was -$258.4 million, 63.72% down from the prior year.
  • EBITDA reached -$81.5 million in Q4 2025 per CLDX's latest filing, down from -$66.6 million in the prior quarter.
  • Across five years, EBITDA topped out at -$13.4 million in Q2 2021 and bottomed at -$81.5 million in Q4 2025.
  • Average EBITDA over 5 years is -$37.0 million, with a median of -$35.1 million recorded in 2024.
  • Peak YoY movement for EBITDA: crashed 173.29% in 2022, then rose 16.37% in 2023.
  • A 5-year view of EBITDA shows it stood at -$20.8 million in 2021, then decreased by 20.73% to -$25.1 million in 2022, then plummeted by 67.76% to -$42.1 million in 2023, then dropped by 16.46% to -$49.1 million in 2024, then tumbled by 66.01% to -$81.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$81.5 million in Q4 2025, -$66.6 million in Q3 2025, and -$56.8 million in Q2 2025.